Genetic protein PD-L1 could have potential as a biomarker for a first-line treatment.
The FDA asked private biotech Genervon to release all available clinical trial data for its experimental ALS treatment.
Schools spent $23 million to bring conflict-of-interest policies in line with regulations aimed at ensuring federally funded research is unbiased.
A Massachusetts court upheld a 2013 decision that the drugmaker failed to provide sufficient risk information for Children's Motrin.
Teva eyes Mylan takeover; Keytruda shown to improve survival, shrink tumors in melanoma; ADHD abuse may follow grads into workforce.
Session: Inspiring the Future 40
Apple's ResearchKit could accelerate the pace at which industry approaches start-ups building products in the patient-facing part of health tech
The FDA approves generic Copaxone; AstraZeneca's experimental lung-cancer drug demonstrates that it can delay disease progression; PhRMA CEO John Castellani to step down
Kane & Finkel co-founder Bob Finkel launched a healthcare consultancy that will seek out limited-commitment projects.
Amgen's attempt to delay Zarxio was denied by a US District Court, which said the argument was speculative.
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.